BR112014014184A2 - triazolopiridinas substituídas e seu uso como inibidores de ttk - Google Patents

triazolopiridinas substituídas e seu uso como inibidores de ttk

Info

Publication number
BR112014014184A2
BR112014014184A2 BR112014014184A BR112014014184A BR112014014184A2 BR 112014014184 A2 BR112014014184 A2 BR 112014014184A2 BR 112014014184 A BR112014014184 A BR 112014014184A BR 112014014184 A BR112014014184 A BR 112014014184A BR 112014014184 A2 BR112014014184 A2 BR 112014014184A2
Authority
BR
Brazil
Prior art keywords
compounds
substituted
ttk inhibitors
triazolopyridines
substituted triazolopyridines
Prior art date
Application number
BR112014014184A
Other languages
English (en)
Inventor
Margret Wengner Antje
Stöckigt Detlef
Kosemund Dirk
Siemeister Gerhard
Bruening Michael
Schulze Volker
Original Assignee
Bayer Ip Gmbh
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh, Bayer Pharma AG filed Critical Bayer Ip Gmbh
Publication of BR112014014184A2 publication Critical patent/BR112014014184A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

resumo patente de invenção: "triazolopiridinas substituídas e seu emprego como inibidores de ttk". a presente invenção refere-se aos compostos de triazolopiridina substituída de fórmula geral (i): (i) em que r1, r2, r3, r4, e r5 são como mencionados na descrição e nas reivindicações, aos métodos de preparar os referidos compostos, às composições e combinações farmacêuticas compreendendo os referidos compostos, ao uso dos referidos compostos para a fabricação de uma composição farmacêutica para o tratamento ou profilaxia de uma doença, bem como aos compostos intermediários úteis na preparação dos referidos compostos. 76/195
BR112014014184A 2011-12-12 2012-12-10 triazolopiridinas substituídas e seu uso como inibidores de ttk BR112014014184A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11193011 2011-12-12
PCT/EP2012/074978 WO2013087579A1 (en) 2011-12-12 2012-12-10 Substituted triazolopyridines and their use as ttk inhibitors

Publications (1)

Publication Number Publication Date
BR112014014184A2 true BR112014014184A2 (pt) 2017-06-13

Family

ID=47427291

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014014184A BR112014014184A2 (pt) 2011-12-12 2012-12-10 triazolopiridinas substituídas e seu uso como inibidores de ttk

Country Status (40)

Country Link
US (1) US9663510B2 (pt)
EP (1) EP2791136B1 (pt)
JP (1) JP6181664B2 (pt)
KR (1) KR20140105552A (pt)
CN (1) CN104114552B (pt)
AP (1) AP4017A (pt)
AR (1) AR089143A1 (pt)
AU (1) AU2012350751B2 (pt)
BR (1) BR112014014184A2 (pt)
CA (1) CA2858683A1 (pt)
CL (1) CL2014001546A1 (pt)
CO (1) CO6980657A2 (pt)
CR (1) CR20140275A (pt)
CU (1) CU20140068A7 (pt)
CY (1) CY1116958T1 (pt)
DK (1) DK2791136T3 (pt)
DO (1) DOP2014000133A (pt)
EC (1) ECSP14004812A (pt)
ES (1) ES2550677T3 (pt)
GT (1) GT201400111A (pt)
HK (1) HK1203200A1 (pt)
HR (1) HRP20151103T1 (pt)
HU (1) HUE025937T2 (pt)
IL (1) IL232930A (pt)
JO (1) JO3111B1 (pt)
MA (1) MA35826B1 (pt)
MX (1) MX2014007057A (pt)
PE (1) PE20141597A1 (pt)
PH (1) PH12014501319A1 (pt)
PL (1) PL2791136T3 (pt)
PT (1) PT2791136E (pt)
RS (1) RS54288B1 (pt)
RU (1) RU2632464C1 (pt)
SG (1) SG11201402820SA (pt)
SI (1) SI2791136T1 (pt)
TN (1) TN2014000254A1 (pt)
UA (1) UA112096C2 (pt)
UY (1) UY34515A (pt)
WO (1) WO2013087579A1 (pt)
ZA (1) ZA201404031B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20150354A1 (es) * 2012-07-10 2015-03-21 Bayer Pharma AG Metodos para preparar triazolopiridinas sustituidas
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
AR096469A1 (es) * 2013-06-06 2015-12-30 Bayer Pharma AG Composiciones farmacéuticas que comprenden compuestos del tipo triazolpiridinas
US9586958B2 (en) * 2013-06-11 2017-03-07 Bayer Pharma Aktiengesellschaft Prodrug derivatives of substituted triazolopyridines
EP3007692A1 (en) * 2013-06-11 2016-04-20 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor
EP2860177A3 (en) 2013-09-20 2015-06-10 Bayer Intellectual Property GmbH Synthesis of functionalized arenes
WO2015176981A1 (en) * 2014-05-19 2015-11-26 Basf Se Fluorescent organic light emitting elements having high efficiency
MA41136A (fr) * 2014-12-09 2017-10-17 Bayer Pharma AG Composés pour le traitement d'un cancer
JP6743015B2 (ja) 2014-12-15 2020-08-19 バイエル ファーマ アクチエンゲゼルシャフト Ｋｓｐ阻害剤の脱グリコシル化抗ｔｗｅａｋｒ抗体との抗体薬物複合体（ａｄｃ類）
CN105985241A (zh) * 2015-01-27 2016-10-05 邵阳学院 α-取代苯乙酸酯类化合物α-糖苷酶抑制作用及其应用
CA2990394A1 (en) 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-tweakr-antibodies
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
TW201800408A (zh) 2016-06-15 2018-01-01 拜耳製藥公司 Mps-1抑制劑
EP3919518A1 (en) 2016-06-15 2021-12-08 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
JP2019535689A (ja) * 2016-10-27 2019-12-12 バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ４，５−縮環１，２，４−トリアゾロン
EP3558387B1 (de) 2016-12-21 2021-10-20 Bayer Pharma Aktiengesellschaft Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
EP3558388A1 (de) 2016-12-21 2019-10-30 Bayer Pharma Aktiengesellschaft Binder-wirkstoff-konjugate (adcs) mit enzymatisch spaltbaren gruppen
CN106831555B (zh) * 2017-01-22 2019-09-24 中国农业大学 吡啶酰胺类化合物及其制备方法与应用
KR20200011060A (ko) 2018-07-23 2020-02-03 삼성디스플레이 주식회사 유기 발광 소자
WO2020161257A1 (en) 2019-02-07 2020-08-13 Bayer Aktiengesellschaft 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as csnk1 inhibitors
KR102661468B1 (ko) 2019-02-15 2024-04-30 삼성디스플레이 주식회사 유기 발광 소자 및 이를 포함한 전자 장치
KR20210059153A (ko) 2019-11-14 2021-05-25 삼성디스플레이 주식회사 유기 발광 소자 및 이를 포함한 장치
WO2023167549A1 (en) * 2022-03-04 2023-09-07 Sillajen, Inc. Pharmaceutical combinations for use in the treatment of neoplastic diseases

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US6693116B2 (en) * 2001-10-08 2004-02-17 Hoffmann-La Roche Inc. Adenosine receptor ligands
AU2004275694B2 (en) 2003-06-30 2008-03-06 Bizbiotech Co., Ltd. Compounds, compositions and methods
WO2007065010A2 (en) 2005-12-02 2007-06-07 Hif Bio, Inc. Anti-angiogenesis compounds
JP5336375B2 (ja) 2006-08-30 2013-11-06 セルゾーム リミテッド キナーゼ阻害剤としてのトリアゾール誘導体
MX2010000716A (es) 2007-07-18 2010-03-26 Novartis Ag Compuestos de heteroarilo biciclicos y su uso como inhibidores de cinasa.
NZ584138A (en) 2007-08-23 2011-10-28 Astrazeneca Ab 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders
CA2691448A1 (en) 2007-08-31 2009-03-05 Dominique Swinnen Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
MX2010005700A (es) 2007-11-27 2010-06-11 Cellzome Ltd Amino triazoles como inhibidores pi3k.
WO2010092015A1 (en) 2009-02-10 2010-08-19 Cellzome Limited Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors
NZ594508A (en) 2009-02-13 2013-12-20 Fovea Pharmaceuticals [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors
CA2760077A1 (en) 2009-04-29 2010-11-04 Marcus Koppitz Substituted imidazoquinoxalines
EP2473498A1 (en) 2009-09-04 2012-07-11 Bayer Pharma Aktiengesellschaft Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
EP2343294A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343295A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
EP2343297A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
US9145399B2 (en) 2010-01-15 2015-09-29 Janssen Pharmaceuticals, Inc. Substituted bicyclic triazole derivatives as gamma secretase modulators
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
JP2011246389A (ja) * 2010-05-26 2011-12-08 Oncotherapy Science Ltd Ｔｔｋ阻害作用を有する縮環ピラゾール誘導体
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
EA023766B1 (ru) * 2011-04-21 2016-07-29 Байер Интеллектчуал Проперти Гмбх Триазолопиридины

Also Published As

Publication number Publication date
CR20140275A (es) 2014-08-13
ZA201404031B (en) 2016-09-28
JP2015500308A (ja) 2015-01-05
PT2791136E (pt) 2015-11-04
MA35826B1 (fr) 2014-12-01
US20150210683A1 (en) 2015-07-30
ES2550677T3 (es) 2015-11-11
JP6181664B2 (ja) 2017-08-16
CN104114552B (zh) 2016-12-28
NZ625815A (en) 2016-07-29
GT201400111A (es) 2015-11-30
EP2791136B1 (en) 2015-07-29
IL232930A (en) 2016-07-31
AP4017A (en) 2017-01-28
CN104114552A (zh) 2014-10-22
ECSP14004812A (es) 2015-11-30
TN2014000254A1 (en) 2015-09-30
AR089143A1 (es) 2014-07-30
HK1203200A1 (en) 2015-10-23
RS54288B1 (en) 2016-02-29
IL232930A0 (en) 2014-08-03
AU2012350751A1 (en) 2014-06-26
AP2014007731A0 (en) 2014-06-30
EP2791136A1 (en) 2014-10-22
CL2014001546A1 (es) 2014-10-24
PH12014501319A1 (en) 2014-09-08
MX2014007057A (es) 2014-08-08
US9663510B2 (en) 2017-05-30
HRP20151103T1 (en) 2015-11-20
DOP2014000133A (es) 2014-07-31
RU2632464C1 (ru) 2017-10-05
SG11201402820SA (en) 2014-06-27
CY1116958T1 (el) 2017-04-05
JO3111B1 (ar) 2017-09-20
CU20140068A7 (es) 2014-12-26
HUE025937T2 (en) 2016-05-30
PE20141597A1 (es) 2014-11-07
SI2791136T1 (sl) 2015-11-30
UA112096C2 (uk) 2016-07-25
AU2012350751B2 (en) 2017-07-06
KR20140105552A (ko) 2014-09-01
UY34515A (es) 2013-07-31
CA2858683A1 (en) 2013-06-20
DK2791136T3 (en) 2015-10-26
CO6980657A2 (es) 2014-06-27
WO2013087579A1 (en) 2013-06-20
PL2791136T3 (pl) 2015-12-31

Similar Documents

Publication Publication Date Title
BR112014014184A2 (pt) triazolopiridinas substituídas e seu uso como inibidores de ttk
BR112012012906A2 (pt) triazolopiridinas
BR112015000615A8 (pt) Purinas macrocíclicas para o tratamento de infecções virais e composição farmacêutica que as compreende
BR112014032809A8 (pt) urolitinas, usos de uma quantidade eficaz de uma urolitina ou um sal farmaceuticamente aceitável da mesma e composição compreendendo as mesmas
BR112014011162A2 (pt) derivados purínicos para o tratamento de infecções virais
BR112015010908A2 (pt) derivado de pirrol sulfonamida, método de preparação para o mesmo e aplicação médica do mesmo
BR112013023876A2 (pt) derivados de pirroltriazinona como inibidores de pi3k
CL2015001304A1 (es) Compuestos derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina que contienen un grupo sulfoximina; composicion farmaceutica; combinacion farmaceutica; y metodo para la preparacion de compuestos.
BR112014010576B8 (pt) compostos inibidores de neprilisina (nep), seus usos, processo de preparação dos compostos e composição farmacêutica compreendendo os compostos
BR112014029185A2 (pt) nucleosídeos de spirooxetano uracila
BR112014008045A2 (pt) benzilindazóis substituídos para uso como inibidores de bub1 cinase no tratamento de doenças hiperproliferativas
BR112013023517A2 (pt) "inibidores de produção de leucotrieno, seus usos, e composição farmacêutica"
ECSP13013011A (es) Triazolopiridinas
BR112013001088A2 (pt) "derivados substituídos como inibidores a quinase de imidazoquinolina"
BR112014010290B8 (pt) Composição farmacêutica na forma de dispersão sólida de ativos específicos em polímeros específicos e uso da composição farmacêutica
BR112015020772A2 (pt) compostos de pirimidina e piridina e seu uso
ECSP12012338A (es) Triazolopiridinas sustituidas
BR112012027803A2 (pt) compostos de pirazol como inibidores de jak
BR112015016325A2 (pt) Composto, composição farmacêutica, e, usos de uma composição, composto, pró-droga ou sal farmaceuticamente aceitável do mesmo
BR112014016157A8 (pt) derivados heterobicíclicos como inibidores de vhc
BR112014001083B8 (pt) Composto, processo para a preparação de um composto, composição farmacêutica, uso da composiçâo farmacêutica e uso do composto
BR112015030774A2 (pt) novos compostos para o tratamento de câncer
BR112015005347A2 (pt) composto, composição farmacêutica, e, método para tratamento ou profilaxia de infecção por hiv ou para tratamento, profilaxia, ou atraso no início de aids
BR112014009760A2 (pt) análogos de ácido siálico, seu uso e composição farmacêutica e composição farmacêutica de liberação sustentada os compreendendo
BR112014016007A2 (pt) derivados de quinazolinona como inibidores de vhc

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]